RAIN — Rain Oncology Income Statement
0.000.00%
Last trade - 00:00HealthcareMicro Cap
- $44.03m
- -$33.29m
Annual income statement for Rain Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 10.8 | 19 | 51.5 | 77.1 |
| Operating Profit | -10.8 | -19 | -51.5 | -77.1 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -10.9 | -21.1 | -51.4 | -75.7 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -10.9 | -21.1 | -51.4 | -75.7 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -10.9 | -21.1 | -51.4 | -75.7 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -10.9 | -21.1 | -51.4 | -75.7 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.42 | -0.613 | -2.65 | -2.71 |
| Dividends per Share |